Organogenesis Holdings Inc [NASDAQ: ORGO] loss -23.32% on the last trading session, reaching $2.29 price per share at the time.
If compared to the average trading volume of 795.10K shares, ORGO reached a trading volume of 2554955 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Organogenesis Holdings Inc [ORGO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORGO shares is $4.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORGO stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Organogenesis Holdings Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 07, 2024. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on June 15, 2023, representing the official price target for Organogenesis Holdings Inc stock. Previously, the target price had yet another raise to $10, while BTIG Research analysts kept a Buy rating on ORGO stock.
The Average True Range (ATR) for Organogenesis Holdings Inc is set at 0.21, with the Price to Sales ratio for ORGO stock in the period of the last 12 months amounting to 0.70. The Price to Book ratio for the last quarter was 1.08, with the Price to Cash per share for the same quarter was set at 0.79. Price to Free Cash Flow for ORGO in the course of the last twelve months was 46.03 with Quick ratio for the last quarter at 2.44.
Trading performance analysis for ORGO stock
Organogenesis Holdings Inc [ORGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.10. With this latest performance, ORGO shares dropped by -12.79% in over the last four-week period, additionally sinking by -1.08% over the last 6 months – not to mention a rise of 16.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORGO stock in for the last two-week period is set at 30.77, with the RSI for the last a single of trading hit 24.50, and the three-weeks RSI is set at 34.74 for Organogenesis Holdings Inc [ORGO]. The present Moving Average for the last 50 days of trading for this stock 2.99, while it was recorded at 2.82 for the last single week of trading, and 3.09 for the last 200 days.
Organogenesis Holdings Inc [ORGO]: A deeper dive into fundamental analysis
Organogenesis Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.44 and a Current Ratio set at 2.80.
Organogenesis Holdings Inc [ORGO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORGO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Organogenesis Holdings Inc go to 2.41%.
An analysis of Institutional ownership at Organogenesis Holdings Inc [ORGO]
The top three institutional holders of ORGO stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in ORGO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in ORGO stock with ownership which is approximately 5.8386%.
